Collaboration Agreement (Details) $ / shares in Units, $ in Thousands		1 Months Ended			3 Months Ended
	Dec. 10, 2021 USD ($) $ / shares shares	Jan. 31, 2022 USD ($)	Dec. 31, 2021 USD ($) target program	Jul. 31, 2020 USD ($)	Mar. 31, 2022 USD ($)	Mar. 31, 2021 USD ($)	Dec. 01, 2021 USD ($)	Jul. 30, 2021 USD ($)	Jun. 30, 2021 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative
Collaboration receivable			$ 300,000		$ 0
Revenue					3,920	$ 286
Upfront payment received from Merck				$ 15,000
Deferred revenue			$ 28,317		30,059
Adjustments
Collaborative Arrangement and Arrangement Other than Collaborative
Deferred revenue									$ 1,900
Maximum | Sales based
Collaborative Arrangement and Arrangement Other than Collaborative
Amount receivable for achievement of milestones				165,000
Maximum | Research Development And Regulatory
Collaborative Arrangement and Arrangement Other than Collaborative
Amount receivable for achievement of milestones				$ 245,000
Eli Lilly
Collaborative Arrangement and Arrangement Other than Collaborative
Number Of Additional Targets | target			3
Number Of Programs | program			6
Number Of Targets | target			5
Collaboration receivable			$ 300,000
Difference between fair value of shares and contract price			37,800
Deferred revenue					333,300		$ 337,800
Revenue					3,800
Proceeds from contracts with customers		$ 300,000
Eli Lilly | Share Purchase Agreement
Collaborative Arrangement and Arrangement Other than Collaborative
Sale of stock, number of shares issued in transaction (in shares) | shares	4,000,000
Sale of stock issue price per share (in dollars per share) | $ / shares	$ 20.00
Sale of stock consideration received on the transaction	$ 80,000
Eli Lilly | Sales Based Milestone
Collaborative Arrangement and Arrangement Other than Collaborative
Amount receivable for achievement of milestones			180,000
Opt Out Milestone Receivable Upon Achievement			360,000
Eli Lilly | Maximum | Research Development And Regulatory
Collaborative Arrangement and Arrangement Other than Collaborative
Amount receivable for achievement of milestones			10,000
Opt Out Milestone Receivable Upon Achievement			$ 70,000
Merck
Collaborative Arrangement and Arrangement Other than Collaborative
Deferred revenue								$ 15,000
Revenue					100	$ 300
Unsatisfied portion of the performance obligation					$ 13,800